ADVERTISEMENT

Thyrocare Q1 Results Review - Margin Thesis Is Starting To Unfold: ICICI Securities

The brokerage retains its Buy rating on the stock with DCF-based revised target price of Rs 825 (Rs 750 earlier), implying 34.9 times FY26E earnings and 19.7 times FY26E Ebitda.

<div class="paragraphs"><p>(Source: Company website)</p></div>
(Source: Company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More